AKT1 and prostate carcinoma: Therefore, although our findings highlight SPON2 as a promising biomarker, direct mechanistic studies in prostate cancer cells are needed to establish whether SPON2 engages PI3K–AKT or Notch pathways in this disease setting (19, 22).